Is Allergan about to get its groove back?
Shares of the Botox maker have been under pressure for the past several months after the company said that Darpin, a highly anticipated drug, had encountered delays.
With the stock down sharply since April, is Allergan (AGN) finally ready to rebound?
That's a pressing question for Jim Cramer.
"I've liked this stock for a long time not only for its breast implants, wrinkle-removers, and eyelash enlargers, but also for its more traditional drug business focused on eye care and migraines," Cramer said.
In April 2012, Cramer called Allergan "a fabulous growth stock."
But even the most fabulous stocks can hit a rough patch.
Shares have been under pressure for the past several months after Allergan said that Darpin, a highly anticipated drug, had encountered delays.
"We also learned that Allergan's second biggest drug, Restasis for dry eye, might face generic competition sooner than expected," Cramer said.
Developments sent investors running for the exits.
Cramer, however, can't help but wonder if sellers will regret their decision. The latest earnings report suggests strength not weakness.
Allergan reported a second-quarter profit of $359.9 million, or $1.19 a share, up from $295.4 million, or 96 cents a share, a year earlier. Revenue increased 10% to $1.6 billion.
Meanwhile, Allergan's medical device segment posted sales of $229.3 million during the quarter, up 7.4% compared with Q2 2012; sales for its breast implant business were up 5.5% to $106.8 million and sales for its facial aesthetics business were $122.5 million, up 9.1%.
Cramer thinks the strong earnings may be just an early glimpse of all the good things to come.
He reminded that "Allergan throws off a lot of cash and it still has consistent earnings per share growth in the mid-teens."
In the past Cramer has cited a slew of other positive catalysts ranging from the company's clear growth path and international expansion plans to its strong balance sheet and shareholder friendly initiatives.
All told, Cramer remains bullish. If anything, he believes the weakness is an opportunity. "I'm a buyer," Cramer said.
More from CNBC
Copyright © 2014 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
The precious metal has suffered as the dollar climbs, geopolitical risks abate and demand from key consumers slows.
VIDEO ON MSN MONEY
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.